Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study

Li, Yuan; Ren, Haitao; Wang, Junmei

doi:10.1186/s12885-019-5879-7

Cited by 31 publications

(36 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In their report from the SEER database (time period 2004-2013, FIGO stages I-III), Li et al found in their matched cohort analysis significant and clinically relevant effects of EBRT, of VBT and of their combination on overall survival, with hazard ratios of 0.65 and 0.62 for the single radiotherapy modalities and 0.47 for the combination [15]. Specific data for individual FIGO stages were not presented.…”

Section: Discussionmentioning

confidence: 99%

“…A significant impact of EBRT on overall survival becomes more prominent in the studies of patient groups including FIGO stages higher than I. Although these mostly do not contain stage-by-stage analyses, pronounced benefits, especially of the combination of EBRT and VBT, have been seen in the stage groups I-III by Li et al, with a hazard ratio of 0.47 [15], and by Stokes et al, with a hazard ratio of 0.74 [19], with both effects being stronger than those of EBRT of VBT alone in these studies, suggesting that patients at stage II or III benefit from radiotherapy consisting of more than VBT alone, possibly the combination of EBRT and VBT.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus

Vordermark

Medenwald

Izaguirre

et al. 2020

Cancers

View full text Add to dashboard Cite

The role of postoperative radiotherapy delivered as external-beam radiotherapy (EBRT), vaginal brachytherapy (VBT) or a combination of both, in the management of carcinosarcoma of the uterus is not clearly defined, as only limited randomized trial data are available, indicating a reduction in locoregional recurrences after EBRT. We performed a structured review of data published from 2010. Although no relevant new data from prospective trials or meta-analyses were identified, 14 analyses of cancer registry data from the United States or Europe, focusing predominantly on the endpoint for overall survival, were identified, four of them using propensity-score matching to compare subgroups treated with vs. without radiotherapy. Although stage-by-stage data are rare, the registry analyses support the idea of a beneficial effect, especially of VBT, on overall survival in International Federation of Gynecology and Obstetrics (FIGO) stage IA patients (to a lesser extent in stage IB). For stages II to III, the data sets indicate the largest effects on overall survival for the combination of EBRT and VBT. In all stages, survival effects of radiotherapy apparently persist when given in addition to chemotherapy. Whereas some studies see the strongest survival effects in patients with positive lymph nodes, propensity-score matched data indicate an overall survival effect of radiotherapy (EBRT + VBT or VBT alone) in FIGO stages I to III regardless of lymph node surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus

Vordermark

Medenwald

Izaguirre

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…23 There is increasing role of adjuvant chemo-radiation now with signi cant overall survival however multiple demographic and clinical factors in uence the choice of adjuvant therapy. 24,25 Despite the use of aggressive therapy, only modest improvement in overall survival is noted over the last few decades with a ve-year overall survival rate of approximately 20-30%. 26 The occurrence of rare tumors like sporadic RH and MMT in the same patient is very rare entity.…”

Section: Discussionmentioning

confidence: 99%

Renal Hemangioblastoma with Mixed Mullerian tumor of endometrium: A tale of two rare primary tumors

Setia

Kumar

Bains

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction: Renal hemangioblastoma (RH) is a very rare benign tumor. Hemangioblastoma most commonly occur in the central nervous system (CNS) and only few cases of RH have been reported as they occur most commonly as asymptomatic masses found incidentally. Mixed Mullerian Tumor (MMT) of the uterus is a rarer and aggressive form of uterine malignancy. The detection of two primary rare tumors incidentally is a rare entity. Case presentation: A 50 years female presented with abnormal uterine bleeding which on endometrial sampling was diagnosed as a rare variety of endometrial cancer i.e., MMT or uterine carcinosarcoma. On preoperative imaging, a renal mass was also detected which was highly vascular and was mimicking Renal Cell Carcinoma (RCC). Fine needle aspiration cytology (FNAC) was done from the renal mass to differentiate between RCC and metastasis but it showed only blood cells. Patient underwent staging laparotomy for endometrial cancer and frozen section examination of the renal mass which was inconclusive with few atypical cells and thus patient underwent radical nephrectomy too. Histopathological examination revealed it to be a RH which is a very rare benign tumor. Discussion: RH is a rare benign tumor which doesn’t require any treatment in majority of the patients. Only 26 cases of RH outside the CNS have been reported till date. MMT is a rare aggressive uterine tumor with an incidence of 1-2 % of all uterine neoplasms, which metastasizes early and thus early identification and treatment is the key. RH needs to be differentiated from RCC to avoid over treatment. Morphological findings are similar in both, preoperative FNAC, PET scan and intraoperative frozen section can be utilized to differentiate in between two in well circumcised tumors and in high suspicion. Occurrence of renal mass as an incidental finding in the preoperative work up of uterine malignancy directed us to the differentials of metastasis or another histologically distinct primary tumor. The presence of two rare primary tumors i.e., RH and MMT in the same patient which are unrelated is a rare entity.

show abstract

“…Based on the GOG 161 study, ifosfamide/paclitaxel is considered the treatment of choice [21] and paclitaxel/ carboplatin is equally effective [22] as adjuvant treatment and was used by our medical oncology team [23]. There is increasing role of adjuvant chemo-radiation now with significant overall survival; however, multiple demographic and clinical factors influence the choice of adjuvant therapy [24,25]. Despite the use of aggressive therapy, only modest improvement in overall survival is noted over the last few decades with a 5-year overall survival rate of approximately 20-30% [26].…”

Section: Discussionmentioning

confidence: 99%

Renal Hemangioblastoma with Mixed Mullerian tumour of endometrium: A tale of two rare primary tumours

et al. 2020

View full text Add to dashboard Cite

Introduction: Renal hemangioblastoma (RH) is a very rare benign tumour. Hemangioblastoma most commonly occurs in the central nervous system (CNS), and only few cases of RH have been reported as they occur most commonly as asymptomatic masses found incidentally. Mixed Mullerian tumour (MMT) of the uterus is a rarer and aggressive form of uterine malignancy. The detection of two primary rare tumours incidentally is a rare entity. Case presentation: A 50-year-old female presented with abnormal uterine bleeding which on endometrial sampling was diagnosed as a rare variety of endometrial cancer, i.e. MMT or uterine carcinosarcoma. On preoperative imaging, a renal mass was also detected which was highly vascular and was mimicking renal cell carcinoma (RCC). Fine needle aspiration cytology (FNAC) was done from the renal mass to differentiate between RCC and metastasis, but it showed only blood cells. Patient underwent staging laparotomy for endometrial cancer and frozen section examination of the renal mass which was inconclusive with few atypical cells, and thus, patient underwent radical nephrectomy too. Histopathological examination revealed it to be a RH which is a very rare benign tumour. Discussion: RH is a rare benign tumour which does not require any treatment in majority of the patients. Only 26 cases of RH outside the CNS have been reported till date. MMT is a rare aggressive uterine tumour with an incidence of 1-2 % of all uterine neoplasms, which metastasizes early, and thus, early identification and treatment is the key. RH needs to be differentiated from RCC to avoid over treatment. Morphological findings are similar in RCC and RH; preoperative FNAC, PET scan, and intraoperative frozen section can be utilized to differentiate the two, in well-circumcised tumours and high index of suspicion. Occurrence of renal mass as an incidental finding in the preoperative work up of uterine malignancy directed us to the differentials of metastasis or another histologically distinct primary tumour. The presence of two rare primary tumours, i.e. RH and MMT in the same patient which are unrelated, is a rare entity.

show abstract

Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study

Cited by 31 publications

References 34 publications

The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus

The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus

Renal Hemangioblastoma with Mixed Mullerian tumor of endometrium: A tale of two rare primary tumors

Renal Hemangioblastoma with Mixed Mullerian tumour of endometrium: A tale of two rare primary tumours

Contact Info

Product

Resources

About